{"id":15014,"date":"2011-05-01T11:05:07","date_gmt":"2011-05-01T11:05:07","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=15014"},"modified":"2014-09-09T13:40:55","modified_gmt":"2014-09-09T13:40:55","slug":"elvitegravircobicistat-and-acid-reducing-agents","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/15014","title":{"rendered":"Elvitegravir\/cobicistat and acid reducing agents"},"content":{"rendered":"<p><strong>HIV-druginteractions.org<\/strong><\/p>\n<p>The effects of omeprazole (20 mg once daily) or famotidine (40 mg once daily) on the pharmacokinetics of EVG and cobicistat were studied in HIV-negative subjects (n=11 per group).<\/p>\n<p>When omeprazole was administered 2 hours prior to elvitegravir and cobicistat the AUC and Cmax of elvitegravir increased by 10% and 16%, but those of cobicistat decreased by 8% and 10%. Separating omeprazole and EVG and cobicistat by 12 h had no effect (&lt;10% change) on the AUC or Cmax of elvitegravir or cobicistat. Administration of famotidine 12 h apart from elvitegravir and cobicistat had no effect (&lt;10% change) on the AUC or Cmax of elvitegravir or cobicistat.<\/p>\n<p>Similar results were observed in a separate study (n=16) of the simultaneous coadministration of famotidine with elvitegravir and cobicistat. No dosing restrictions are necessary on the administration of EVG and cobicistat with proton pump inhibitors.<\/p>\n<p>Based on the available data, elvitegravir and cobicistat should be administered simultaneously with, and\/or 12 hours after, dosing of H2 receptor antagonists.<\/p>\n<p>Reference:<\/p>\n<p>Mathias A et al. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat boosted elvitegravir. 12th International Workshop on Clinical Pharmacology of HIV Therapy, 13\u0096-15 April 2011, Miami. Poster abstract: P_13<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIV-druginteractions.org The effects of omeprazole (20 mg once daily) or famotidine (40 mg once daily) on the pharmacokinetics of EVG and cobicistat were studied in HIV-negative subjects (n=11 per group). When omeprazole was administered 2 hours prior to elvitegravir and &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3,34],"tags":[135],"class_list":["post-15014","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","category-pk-and-drug-interactions","tag-pk-workshop-12th-2011"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/15014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=15014"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/15014\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=15014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=15014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=15014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}